Combined administration of captopril with an antihypertensive Val-Tyr di-peptide to spontaneously hypertensive rats attenuates the blood pressure lowering effect

Life Sciences

Volumn 79, Issue 26, 2006, Pages 2492-2498

  Matsui, Toshiro ^a   Zhu, Xiao Lin ^a   Watanabe, Keisuke ^a   Tanaka, Keisuke ^a   Kusano, Yoko ^a   Matsumoto, Kiyoshi ^a  

^a Kyushu Universitay   (Japan)

Author keywords

Absorption; Angiotensin I converting enzyme inhibitor; Captopril; Combined administration; Hypertension; Peptide

Indexed keywords

ANTIHYPERTENSIVE AGENT; CAPTOPRIL; DIPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TRANSPORT; DRUG UPTAKE; HYPERTENSION; JEJUNUM; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL TRANSPORT; BLOOD PRESSURE; CAPTOPRIL; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HYPERTENSION; JEJUNUM; KINETICS; MALE; RATS; RATS, INBRED SHR;

EID: 33751005583     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.08.013     Document Type: Article

References (21)

1. Anand B.S., Patel J., and Mitra A.K. Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-caco-2. Journal of Pharmacology and Experimental Therapeutics 304 (2003) 784-791
2. Arai S., Osawa T., Ohigashi H., Yoshikawa M., Kaminogawa S., Watanabe M., Ogawa T., Okubo K., Watanabe S., Nishino H., Shinohara K., Esashi T., and Hirahara T. A mainstay of functional food science in Japan-History, present status, and future outlook. Bioscience, Biotechnology and Biochemistry 65 (2001) 1-13
3. Aykin N., Neal R., Yusof M., and Ercal N. Determination of captopril in biological samples by high-performance liquid chromatography with ThioGlo™3 derivatization. Biomedical Chromatography 15 (2001) 427-432
4. Bai J.P.F., and Amidon G.L. Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharmaceutical Research 9 (1992) 969-978
5. Fujita H., and Yoshikawa M. LKPNM, a prodrug-type ACE inhibitory peptide derived from fish protein. Immunopharmacology 44 (1999) 123-127
6. Ganapathy M.E., Brandsch M., Prasad P.D., Ganapathy V., and Leibach F.H. Differential recognition of β-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. Journal of Biological Chemistry 270 (1995) 25672-25677
7. Hata Y., Yamamoto M., Ohni M., Nakajima K., Nakamura Y., and Takano T. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. American Journal of Clinical Nutrition 64 (1996) 767-771
8. Hooper N.M. Angiotensin converting enzyme: implications from molecular biology for its physiologically functions. International Journal of Biochemistry 23 (1991) 641-647
9. Kawasaki T., Seki E., Osajima K., Yoshida M., Asada K., Matsui T., and Osajima Y. Antihypertensive effect of Valyl-Tyrosine, a short chain peptide derived from sardine muscle hydrolysate. Journal of Human Hypertension 14 (2000) 519-523
10. Kripalani K.J., McKinstry D.N., Singhvi S.M., Willard D.A., Vukovich R.A., and Migdalof B.H. Disposition of captopril in normal subjects. Clinical Pharmacology and Therapeutics 27 (1980) 636-641
11. +/peptide symporter. Pharmaceutical Research 16 (1999) 609-615
12. Matsui T., Hayashi A., Tamaya K., Matsumoto K., Kawasaki T., Murakami K., and Kimoto K. Depressor effect induced by dipeptide, Val-Tyr, in hypertensive transgenic mice is in part due to the suppression of human circulating renin-angiotensin system. Clinical and Experimental Pharmacology and Physiology 30 (2003) 262-265
13. Matsui T., Imamura M., Oka H., Osajima K., Kimoto K., Kawasaki T., and Matsumoto K. Tissue distribution of antihypertensive dipeptide, Val-Tyr, after its single oral administration to spontaneously hypertensive rats. Journal of Peptide Science 10 (2004) 535-545
14. Matsufuji H., Matsui T., Seki E., Osajima K., Nakashima M., and Osajima Y. Angiotensin I-converting enzyme inhibitory peptides in an alkaline protease hydrolysate derived from sardine muscle. Bioscience, Biotechnology, and Biochemistry 58 (1994) 2244-2245
15. Meredith D., Temple C.S., Guha N., Sword C.J., Boyd C.A.R., Collier I.D., Morgan K.M., and Bailey P.D. Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1. European Journal of Biochemistry 367 (2000) 3723-3728
16. Olentarutti B.I., Peterson A.L., Sjoberg A.K., Anderberg E.K.I., Utter L.M., and Ungell A.-L.B. Evaluation of viability of excised rat intestinal segments in Ussing chamber: investigation of morphology, electrical parameters, and permeability characteristics. Pharmaceutical Research 16 (1999) 446-454
17. Schoenmakers R.G., Stehouwer M.C., and Tukker J.J. Structure-transport relationship for the intestinal small-peptide carrier: is the carbonyl group of the peptide bond relevant for transport?. Pharmaceutical Research 16 (1999) 62-68
18. Sekiya S., Kobayashi Y., Kita E., Imamura Y., and Toyama S. Antihypertensive effects of tryptic hydrolysate of casein on normotensive and hypertensive volunteers. Journal of Japan Society of Nutrition and Food Science 45 (1992) 513-517
19. Tsuji A., and Tamao I. Carrier-mediated intestinal transport of drugs. Pharmaceutical Research 13 (1996) 963-977
20. Yang C.Y., Dantzig A.H., and Pidgeon C. Intestinal peptide transport systems and oral availability. Pharmaceutical Research 16 (1999) 1331-1343
21. Zhu T., Chen X.-Z., Steel A., Hdiger M.A., and Smith D.E. Differential recognition of ACE inhibitors in Xenopus lavevis oocytes expressing rat PEPT1 and PEPT2. Pharmaceutical Research 17 (2000) 526-532